3.965

0.16% -0.005

Protara Therapeutics Inc (TARA)

Overview News Price History Option Chain Financials Discussions Forecast

Protara Therapeutics Inc stock is traded at $3.965, with a volume of 144.16K. It is down -0.16% in the last 24 hours and down -3.32% over the past month. Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.

Previous Close:

$3.97

Open:

$3.96

24h Volume:

144.16K

Relative Volume:

0.22

Market Cap:

$234.31M

Revenue:

Net Income/Loss:

$-57.44M

P/E Ratio:

-2.9676

EPS:

-1.3361

Net Cash Flow:

$-56.46M

1W Performance:

-3.56%

1M Performance:

-3.32%

6M Performance:

-39.48%

1Y Performance:

+30.82%

1-Day Range:

$3.93

$4.01

1-Week Range:

$3.78

$4.03

52-Week Range:

$2.97

$7.82

Protara Therapeutics Inc Stock (TARA) Company Profile

Name

Protara Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

646-844-0337

Address

345 PARK AVENUE SOUTH, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

TARA's Discussions on Twitter

Compare TARA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TARA Protara Therapeutics Inc	3.965	234.61M	0	-57.44M	-56.46M	-1.3361
VRTX Vertex Pharmaceuticals Inc	515.90	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.46	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.29	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	213.97	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.63	39.31B	5.76B	514.49M	1.10B	4.4813

Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-04-26	Initiated	JP Morgan	Overweight
Jan-07-26	Initiated	Piper Sandler	Overweight
Apr-16-25	Initiated	Scotiabank	Sector Outperform
Mar-14-25	Initiated	Cantor Fitzgerald	Overweight
Jul-10-23	Resumed	Guggenheim	Buy
Jun-04-21	Initiated	H.C. Wainwright	Buy
Feb-17-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Cowen	Outperform
Jul-29-20	Initiated	Guggenheim	Buy

View All

Protara Therapeutics Inc Stock (TARA) Latest News

03:16 AM

Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat

03:16 AM

Aug 15, 2026

Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 14, 2026

HC Wainwright Issues Negative Forecast for TARA Earnings - MarketBeat

Aug 14, 2026

Protara Therapeutics, Inc. Actuals & Estimates (NASDAQ:TARA) - TradingView

Aug 14, 2026

Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA - MarketBeat

Aug 14, 2026

Aug 13, 2026

Janus Henderson Group (TARA holder) reports 8.4% Protara Therapeutics stake via Managed Portfolios - Stock Titan

Aug 13, 2026

Aug 12, 2026

H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $27 - Moomoo

Aug 12, 2026

JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Aug 12, 2026

Protara Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Aug 12, 2026

Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus

Aug 12, 2026

Aug 11, 2026

Form 8K Protara Therapeutics Inc For: 11 August By Investing.com - Investing.com South Africa

Aug 11, 2026

Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results - MarketBeat

Aug 11, 2026

Protara Therapeutics (TARA) Advances Clinical Trials Amid Mixed Market Signals - GuruFocus

Aug 11, 2026

Protara Therapeutics, Inc. 2Q 2026: Net income $(21.7)M, EPS $(0.36) — 10-Q Summary - TradingView

Aug 11, 2026

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - The Manila Times

Aug 11, 2026

Protara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 11, 2026

Protara Therapeutics reports Q2 2026 net loss $21.7M, cash ~$162M to fund operations into 2028 - TradingView

Aug 11, 2026

Protara Therapeutics: Q2 Earnings Snapshot - AOL.com

Aug 11, 2026

Protara Posts $21.7 Million Q2 Loss as Pipeline Milestones Near - Quiver Quantitative

Aug 11, 2026

Protara Therapeutics rated Buy with $9.96 fair value, advancing treatments for NMIBC and choline deficiency. - Pluang

Aug 11, 2026

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline - Seeking Alpha

Aug 11, 2026

Aug 07, 2026

Protara Therapeutics (TARA) Rises Modestly to $4.12 as Stock Consolidates Between Key LevelsDark Pool Sentiment - dars.gov.et

Aug 07, 2026

Aug 04, 2026

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Aug 04, 2026

Jul 27, 2026